Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Proteostasis Therapeutics (PTI) Surges 50% on FDA Breakthrough Therapy Designation for PTI-428
March 13, 2018 9:05 AM EDTProteostasis Therapeutics (NASDAQ: PTI) surges 50% in pre-open trading after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for PTI-428, the Companys cystic fibrosis transmembrane conductance regulator (CFTR) amplifier.
... MoreProteostasis Therapeutics (PTI): Incrementally Positive on FDA Breakthrough Designation - Baird
March 13, 2018 6:44 AM EDTBaird analyst Brian Skorney is incrementally positive on Proteostasis Therapeutics' (NASDAQ: PTI) FDA breakthrough designation for PTI-428.
Skorney said the FDA designation should provide additional validation that the results demonstrated are clinically meaningful.
"We believe shares could be up significantly given... More
